Clinical Trials Logo

Radiotherapy Side Effect clinical trials

View clinical trials related to Radiotherapy Side Effect.

Filter by:

NCT ID: NCT05614700 Not yet recruiting - Prostate Cancer Clinical Trials

Prostate Reirradiation Toxicity Outcomes Feasibility Study

RO-PIP
Start date: November 15, 2022
Phase: N/A
Study type: Interventional

The RO-PIP trial aims to determine the feasibility of recruitment to a trial randomising patients to salvage ultra-hypofractionated external beam radiotherapy or high dose rate brachytherapy and provide prospective data on patient recorded toxicity outcomes that will inform a future phase III trial.

NCT ID: NCT05561803 Not yet recruiting - Breast Cancer Clinical Trials

The Use of Photobiomodulation in the Management of Radiodermatitis in Breast Cancer Patients

Start date: November 2022
Phase:
Study type: Observational

It is estimated that there will be 670,000 new cases of cancer worldwide in 2020-2022 and it is known that the most commonly instituted treatments in cancer are chemotherapy, radiotherapy and surgery. However, these treatments have undesirable side effects, such as Radiodermatitis after Radiotherapy (RD). In fact, the prevalence of possible side effects after radiotherapy is estimated to be 80 to 90%. Radiotherapy complications are associated with a negative impact on patients' quality of life and few supportive measures are available for such complications. Thus, the management of these side effects has been studied in the literature until the present day. On the other hand, Photobiomodulation (PBM) has an important role in wound repair and tissue regeneration, as it influences the different phases of lesion resolution, including the inflammatory phase, the proliferative phase and the remodeling phase. Thus, the aim of this study is to report a case series of Breast Cancer Patients diagnosed with radiotherapy-induced acute radiodermatitis treated with PBM. This is a case series report and the study data will be extracted from the medical records of sixty breast cancer patients with grade 2 or 3 RD followed up from September 2021 at the Laser Therapy Outpatient Clinic in a Universitarian Hospital. The outcomes are the size of the lesion, the presence of pain assessed by the Visual Analogue Scale (VAS) and the RTOG Scale (Radiation Therapy Oncology Group Scale) to assess the degree of Radiodermatitis before and after PBM therapy. The data will be subjected to a statistical analysis and will be discussed. Data with positive or negative results will be reported.

NCT ID: NCT05557825 Not yet recruiting - Clinical trials for Head and Neck Cancer

The Use of Photobiomodulation in the Management of Radiodermatitis in Head and Neck Cancer Patients

Start date: October 2022
Phase:
Study type: Observational

It is estimated that there will be 670,000 new cases of cancer worldwide in 2020-2022 and it is known that the most commonly instituted treatments in cancer are chemotherapy, radiotherapy and surgery. However, these treatments have undesirable side effects, such as Radiodermatitis after Radiotherapy (RD). In fact, the prevalence of possible side effects after radiotherapy is estimated to be 80 to 90%. Radiotherapy complications are associated with a negative impact on patients' quality of life and few supportive measures are available for such complications. Thus, the management of these side effects has been studied in the literature until the present day. On the other hand, Photobiomodulation (PBM) has an important role in wound repair and tissue regeneration, as it influences the different phases of lesion resolution, including the inflammatory phase, the proliferative phase and the remodeling phase. Thus, the aim of this study is to report a case series of Head and Neck Cancer Patients diagnosed with radiotherapy-induced acute radiodermatitis treated with PBM. This is a case series report and the study data will be extracted from the medical records of four head and neck cancer patients with grade 2 or 3 RD followed up from September 2021 at the Laser Therapy Outpatient Clinic in a Universitarian Hospital. The outcomes are the size of the lesion, the presence of pain assessed by the Visual Analogue Scale (VAS) and the RTOG Scale (Radiation Therapy Oncology Group Scale) to assess the degree of Radiodermatitis before and after PBM therapy. The data will be subjected to a statistical analysis and will be discussed. Data with positive or negative results will be reported.

NCT ID: NCT05548504 Not yet recruiting - Frailty Clinical Trials

Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC

HERAN2
Start date: October 1, 2022
Phase: Phase 2
Study type: Interventional

Aim To test if proton therapy can improve survival compared to photon therapy in patients with locally advanced NSCLC who are not candidates for standard definitive chemo-radiotherapy. Hypothesis The trial hypothesis is that proton therapy is less toxic than photon therapy in fragile patients and that this difference will mitigate to a difference in overall survival. Design Multicentre, randomized phase II study 1:1 Sample size 182 patients (91 in each arm) Treatment Radiotherapy (inhomogeneous dose distribution) 50 Gy/ 24 fraction Endpoint Primary: Overall survival at 12 months Secondary: progression free survival, time to loco-regional and distant failure, pattern of failure, acute and late toxicity, quality of life, patient compliance.

NCT ID: NCT05543239 Recruiting - Neuropathic Pain Clinical Trials

Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation on Radiotherapy-Related Neuropathic Pain

RELAX
Start date: September 16, 2022
Phase: N/A
Study type: Interventional

This multi-center, randomized, double-blind, sham-controlled trial aims to investigate the effect and safety of TaVNS in treating radiotherapy-related neuropathic pain.

NCT ID: NCT05511740 Completed - Cervical Cancer Clinical Trials

Circadian as A Prognostic Factor For Radiation Response in Cervical Cancer

Start date: January 2010
Phase: N/A
Study type: Interventional

The study was a Randomized Clinical Trial (RCT) or clinical trial comparing the results of radiation treatment of 2 treatment groups, i.e. subject groups irradiated in the morning and in the afternoon, to check melatonin levels in cervical cancer patients. Since it is known that the function of melatonin is as an antiproliferation substance or hormone, induces apoptosis, inhibits invasion and metastasis.

NCT ID: NCT05478850 Completed - Childhood Cancer Clinical Trials

Inadvertent Hypothermia or Hyperthermia in Pediatric Radiotherapy Practices Under Anesthesia

Start date: August 1, 2022
Phase:
Study type: Observational

In prospective, observational cohort study, changes in body temperature will be investigated before the procedure and during recovery in Radiotherapy patients aged 0-18 years who need sedation due to childhood malignancies. The aims of this study were to measure the incidence and magnitude of changes in body temperature in children undergoing sedation or general anesthesia for Radiotherapy, and to determine their effects on the recovery process.

NCT ID: NCT05385250 Recruiting - Anal Cancer Clinical Trials

Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II

DACG-II
Start date: August 23, 2021
Phase: N/A
Study type: Interventional

This study proposal includes a prospective clinical trial of bone sparing treatment planning in anal cancer patients. We seek to lower the risk of bone damage, while adhering with the constrains to the bowel, bladder and other conventional Organs At Risk, and finally to describe the fraction of pelvic insufficiency fractures in patients treated with optimized radiotherapy.

NCT ID: NCT05354596 Not yet recruiting - Lung Cancer Clinical Trials

A Multicenter Phase II Study of Stereotactic Radiotherapy for Centrally Located Lung Tumors (STRICT-LUNG STUDY) and Ultra-centrally Located Lung Tumors (STAR-LUNG STUDY).

STRICTSTARLUNG
Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

An open-label phase II study, investigating toxicity, treatment efficacy and the local tumor control rate in 69 patients with centrally located tumors and in 69 patients with ultra-centrally located tumors in the lung. Treatment and patient outcomes will be recorded. Centrally located tumors are treated on standard-linacs with daily CBCT image-guidance and plan adaptation. Ultra-centrally tumors are treated on MR-linacs with daily MR-guided plan-adaptation.

NCT ID: NCT05350475 Recruiting - Prostate Cancer Clinical Trials

Protons vs. Photons for High-risk Prostate Cancer

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to assess late gastro-intestinal side-effects comparing proton therapy to photon therapy in high-risk prostate cancer patients receiving whole pelvic irradiation.